Docline Prepares a New Round of 6 Million for 2024

Docline continues to seek capital. The digital health company from Malaga will open a new investment round of between €6 million and €7 million in 2024, according to Omar Najid, CEO and co-founder of the group.

The company, which has closed another round of three million euros this year, will seek to strengthen its presence in the international markets where it is present: Morocco, Chile, Mexico, Brazil, Colombia, and Peru; where the company generates 20% of its turnover, and which plans to increase to 40% in 2024.

This 2023, the company will allocate €1.5 million to research and development (R&D), with investments “aimed at continuing to bet on digitization, developing an API model that allows our clients to integrate our technology in an agile and offer mobile solutions to third parties”, according to Najid.

Read more about Docline and find the most important business headlines of the day with the Born2Invest mobile app.

Docline has closed an investment round of €3 million in 2022

Specifically, Docline offers the possibility of automating processes and digitizing services by caring for patients remotely through a complete suite of more than fifteen functionalities, from communication (video consultations, medical chat, and phone calls) to issuing and receiving private and approved electronic prescriptions thanks to its integration with pharmacies in Spain.

The Malaga-based company works with insurers, hospitals, clinics, and healthcare professionals. For this year, the group hopes to multiply its income, although it does not detail the exact figure it expects to achieve. Currently, the company has 38 people on its staff, of which 65% are from the technological team.

Docline has a community of almost 5,000 digital doctors from more than 35 specialties who are experts in telemedicine and who offer uninterrupted healthcare. The company was founded in 2016 at the initiative of Najid and Roberto Medina.

The company has 38 people on its staff and a network of 5,000 associated doctors

To accelerate its expansion, Docline has hired Mayka Palacios as its medical director. Before she joined the company, the executive was the regional medical director of Sanitas and former manager of the San Juan de Dios Santurce Hospital.

The group ensures that Docline responds to four current problems. The first place, the inability of the public health system to meet the health demand; second, the increase in the average age of the population; third, the increase in the contracting of private insurance, with one million new insured since 2019; and, finally, the decline in productivity in Spanish companies, including those in the health field.

Docline maintains an agreement with Mapfre, with whom it offers digital health programs to the company’s policyholders; with the Ballesol retirement home company, to whose patients it offers care by video consultation at all hours; and with the elderly care services company Cuideo, with whom it collaborates to offer video consultation services. 

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.